Overview of extracorporeal liver support systems and clinical results.
Patients with acute liver failure (ALF) continue to have an almost 50% mortality rate despite improvements associated with the use of orthotopic liver transplantation (OLT). Numerous ex vivo methods have been developed in attempts to improve patient survival. These methods can be divided into three groups: detoxification (e.g., dialysis, charcoal adsorption, plasma exchange), which only provides excretory function; ex vivo liver perfusion (e.g., whole organ or tissue perfusion), which provides some metabolic function; and bioartificial or cell-based systems, which combine elements of the first two methods. Clinical trials have shown minimal efficacy of the various detoxification methods in terms of ALF patient survival, while the relative success of OLT has shown the importance of providing metabolic as well as excretory functions. Attempts to provide those additional functions with ex vivo tissue perfusion have been fraught with complications such as clotting and acute tissue rejection, leading to the conceptual development of cell-based bioreactor systems. A number of these bioartificial systems have been clinically evaluated, and the preliminary patient survival rates have encouraged further work in this area.
McLaughlin
B E
BE
Circe Biomedical, Inc., Lexington, Massachusetts 02421, USA.
Tosone
C M
CM
Custer
L M
LM
Mullon
C
C
D000818:Animals; D006440:Hemofiltration; D006801:Humans; D017114:Liver Failure, Acute / Q000097:blood / Q000628:therapy*; D019164:Liver, Artificial; D010956:Plasmapheresis; D006435:Renal Dialysis